Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 1/20 | 1.00 |
| ▸ | GAA | P10253 | 2/20 | 0.85 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.85 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.85 |
| ▸ | TTR | P02766 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | PDE4A | P27815 | 1/20 | 0.39 |
| ▸ | KDR | P35968 | 1/20 | 0.39 |
| ▸ | APEX1 | P27695 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1176879 | 1.00 | MEN1 (1.00) | MEN1KMT2AGAAKDM4ECYP2C9 | |
| SCHEMBL11554769 | 1.00 | MEN1 (1.00) | MEN1KMT2AGAAKDM4ECYP2C9 | |
| SCHEMBL27350 | 1.00 | MEN1 (1.00) | MEN1KMT2AGAAKDM4ECYP2C9 | |
| SCHEMBL11584070 | 1.00 | MEN1 (1.00) | MEN1KMT2AGAAKDM4ECYP2C9 | |
| SCHEMBL11559655 | 1.00 | MEN1 (1.00) | MEN1KMT2AGAAKDM4ECYP2C9 | |
| SCHEMBL25148109 | 1.00 | MEN1 (1.00) | MEN1KMT2AGAAKDM4ECYP2C9 | |
| Morpholine SCHEMBL8649532 | 1.00 | MEN1 (1.00) | MEN1KMT2AGAAKDM4ECYP2C9 | |
| SCHEMBL7747664 | 1.00 | MEN1 (1.00) | MEN1KMT2AGAAKDM4ECYP2C9 | |
| SCHEMBL111814 | 1.00 | MEN1 (1.00) | MEN1KMT2AGAAKDM4ECYP2C9 | |
| SCHEMBL897208 | 1.00 | MEN1 (1.00) | MEN1KMT2AGAAKDM4ECYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1402 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026106998-A1 | PROSTATE-SPECIFIC MEMBRANE ANTIGEN (PSMA)-TARGETED POLY(ADP-RIBOSE) POLYMERASE (PARP) INHIBITOR AND RELATED COMPOSITION AND METHOD OF USE | PURDUE RESEARCH FOUNDATION (US) | 2026-05-21 | — | — | WO | claimed |
| CN-122060129-A | High-temperature-resistant filtrate reducer, preparation method thereof and drilling fluid | 中石化石油工程技术服务股份有限公司 | 2026-05-19 | — | — | CN | claimed |
| CN-122005879-A | Modified GRPR antagonist peptides for cancer imaging and treatment | 慕尼黑工业大学 | 2026-05-12 | — | — | CN | claimed |
| EP-4735906-A1 | SYSTEMS AND METHODS FOR HYPERPOLARIZED NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY AND MAGNETIC RESONANCE IMAGING | NVision Imaging Technologies GmbH (DE) | 2026-05-06 | — | — | EP | claimed |
| US-12616761-B2 | CXCR4-targeting compounds | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2026-05-05 | — | — | US | claimed |
| EP-4721765-A1 | BI-FUNCTIONALIZED ANTIBODY CONJUGATES AGAINST THE ENDOTHELIN RECEPTOR B | Commissariat à l'Energie Atomique et aux Energies Alternatives (FR) | 2026-04-08 | — | — | EP | claimed |
| EP-4719486-A1 | CONJUGATES AND USES THEREOF | Full-Life Technologies UK Limited (GB) | 2026-04-08 | — | — | EP | claimed |
| EP-4719498-A1 | RADIOLIGANDS FOR TARGETING CELL SURFACE RECEPTORS AND USES THEREOF | Full-Life Technologies UK Limited (GB) | 2026-04-08 | — | — | EP | claimed |
| EP-4704924-A1 | RADIONUCLIDE-LOADED NANOPARTICLES FOR FOCAL TISSUE ABLATION | TRANSLATIONAL AND FUNDAMENTAL TECHNOLOGIES INSTITUTE LLC (US) | 2026-03-11 | — | — | EP | claimed |
| US-20260034252-A1 | FIBROBLAST ACTIVATION PROTEIN-TARGETED COMPOSITIONS AND METHODS OF USE THEREOF | RATIO THERAPEUTICS INC (US) | 2026-02-05 | — | — | US | claimed |
| EP-0554358-A1 | CHELATING AGENTS | RESEARCH CORPORATION TECHNOLOGIES, INC. (US) | 1993-08-11 | — | — | EP | claimed |
| US-5169751-A | Using crown ethers, containing nitrogen, complexed with gold or palladium compounds | FORTE PHOTOCHEMICAL INDUSTRY (HU) | 1992-12-08 | — | — | US | claimed |
| WO-1992005804-A1 | CHELATING AGENTS | BRUNSWICK CORPORATION (US) | 1992-04-16 | — | — | WO | claimed |
| WO-1990014343-A1 | METHOD FOR THE PREPARATION OF ACTIVE INGREDIENTS AND PHARMACEUTICAL COMPOSITIONS FOR DECORPORATING RADIOACTIVE ISOTOPES FROM LIVING ORGANISMS | ORSZÁGOS 'FREDERIC JOLIOT-CURIE' SUGÁRBIOLÓGIAI ÉS SUGÁREGÉSZSÉGÜGYI KUTATÓ INTÉZET (HU) | 1990-11-29 | — | — | WO | claimed |
| EP-0369733-A2 | Fluorescent indicator dyes for alkali metal cations, their preparation and use | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1990-05-23 | — | — | EP | claimed |
| EP-0287818-A2 | Polymerisable compounds and mixture containing them polymerisable by radiation | HOECHST AKTIENGESELLSCHAFT (DE) | 1988-10-26 | — | — | EP | claimed |
| US-4597903-A | Process for the direct preparation of N,N-disubstituted derivatives for 4,13-diaza-18-crown-6 | UNIVERSITY OF MARYLAND (US) | 1986-07-01 | — | — | US | claimed |
| US-4176131-A | Chemical process | BRISTOL-MYERS COMPANY (US) | 1979-11-27 | — | — | US | claimed |
| US-4156683-A | CROWN COMPOUNDS USED AS CHELATING AGENTS | SCHERING CORPORATION (US) | 1979-05-29 | — | — | US | claimed |
| US-3966766-A | CHELATING AGENTS | SCHERING CORPORATION (US) | 1976-06-29 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12616761-B2 | CXCR4-targeting compounds | CXCR4, CXCR2, CXCR3 | MEN1 3462/4885KMT2A 3174/4885GAA 3380/4885 |
| US-20260034252-A1 | FIBROBLAST ACTIVATION PROTEIN-TARGETED COMPOSITIONS AND METHODS OF USE THEREOF | CCR6, OGFRL1, IL6ST | MEN1 4466/4885KMT2A 4842/4885GAA 3120/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.